



#9/B  
SEP 26 2001  
9-28-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Tschope, et. al.

Atty. Docket No.: 100564-00002

Application Number: 09/508,510

Group Art Unit: 1646

Filed: May 26, 2000

Examiner: Prasad, Sarada

For: LIQUID INTERFERON- $\beta$  FORMULATIONS

RECEIVED  
SEP 26 2001  
TC 1700

STATEMENT UNDER 37 C.F.R. § 1.825

Commissioner of Patents  
Washington, D.C. 20231

September 24, 2001

Sir:

In accordance with 37 C.F.R. § 1.825, applicant hereby submits the revised Sequence Listing for the above-referenced application in both paper copy and in computer readable form.


The name of the file on the computer readable form is 100564-00002.txt. The paper copy and the computer readable form are the same. Please note that no new matter has been added.

In the event that this paper is not considered timely filed, applicant hereby petitions for an appropriate extension of time. If necessary, please charge any

additional amounts or credit any overpayments to Direct Deposit Account Number 01-2300.

Respectfully Submitted,

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC

A handwritten signature in black ink, appearing to read "Lynn A. Bristol". The signature is fluid and cursive, with the last name "Bristol" being more prominent.

Lynn A. Bristol  
Reg. No. 48, 898  
Attorney for Applicant

Arent Fox Kintner Plotkin & Kahn, PLLC  
1050 Connecticut Avenue, N.W.  
Washington, DC 20036-5339  
(202) 857-6000  
(202) 857-6395 (fax)

Received

SEP 14 2001

Arent Fox



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/500,510 05/26/00 TSCHOPE

M P100564-0000

004372

HM22/0913

ARENT FOX KINTNER PLOTKIN & KAHN  
1050 CONNECTICUT AVENUE, N.W.  
SUITE 600  
WASHINGTON DC 20036



EXAMINER

PRASAD, S

ART UNIT

PAPER NUMBER

1646

DATE MAILED:

09/13/

TECH CENTER 1609/2900

SEP 26 2001

RECEIVED

Please find below and/or attached an Office communication concerning this application proceeding.

Commissioner of Patents and Trademarks

DOCKETED BY

DATE

RECEIVED

SEP 26 2001

TECH CENTER 1600/2900

# Notice to Comply

Applicati n No.

09 508510

Applicant(s)

Techhope et al

Examiner  
Sarada Prasad

Art Unit  
1646

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

### Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216


For CRF Submission Help, call (703) 308-4212


PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**





## SEQUENCE LISTING

RECEIVED  
SEP 26 2001  
TECH CENTER 1600/2900

<110> Tschope, Michael  
Siklosi, Thomas  
Schroeder, Peter  
Hofer, Hans

<120> Liquid Interferon-B Formulations

<130> 100564-00002

<140> 09/508,510

<141> 2000-05-26

<150> 97116562.6

<151> 1997-09-23

<150> PCT/EP98/06065

<151> 1998-09-23

<160> 14

<170> PatentIn version 3.1

B<sub>1</sub>  
<210> 1

<211> 7

<212> PRT

<213> Homo sapiens

<400> 1

Glu Asp Phe Thr Arg Gly Lys  
1 5

<210> 2

<211> 6

<212> PRT

<213> Homo sapiens

<400> 2

Thr Val Leu Glu Glu Lys  
1 5

<210> 3

<211> 7

<212> PRT

<213> Homo sapiens

<400> 3

Gln Leu Gln Gln Phe Gln Lys  
1 5

<210> 4  
<211> 8  
<212> PRT  
<213> Homo sapiens

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa is methionine sulphoxide

<400> 4

Leu Xaa Ser Ser Leu His Leu Lys  
1 5

<210> 5  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 5

Leu Met Ser Ser Leu His Leu Lys  
1 5

B<sub>1</sub>

<210> 6  
<211> 12  
<212> PRT  
<213> Homo sapiens

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Xaa is methionine sulphoxide

<400> 6

Asp Arg Xaa Asn Phe Asp Ile Pro Glu Glu Ile Lys  
1 5 10

<210> 7  
<211> 11  
<212> PRT  
<213> Homo sapiens

<400> 7

Arg Tyr Tyr Gly Arg Ile Leu His Tyr Leu Lys  
1 5 10

<210> 8

<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 8

Asp Arg Met Asn Phe Asp Ile Pro Glu Glu Ile Lys  
1 5 10

<210> 9  
<211> 14  
<212> PRT  
<213> Homo sapiens

<400> 9

Leu Leu Trp Gln Leu Asn Gly Arg Leu Glu Tyr Cys Leu Lys  
1 5 10

<210> 10  
<211> 19  
<212> PRT  
<213> Homo sapiens

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa is methionine sulphoxide

<400> 10

Xaa Ser Tyr Asn Leu Leu Gly Phe Leu Gln Arg Ser Ser Asn Phe Gln  
1 5 10 15

Cys Gln Lys

<210> 11  
<211> 19  
<212> PRT  
<213> Homo sapiens

<400> 11

Met Ser Tyr Asn Leu Leu Gly Phe Leu Gln Arg Ser Ser Asn Phe Gln  
1 5 10 15

Cys Gln Lys

<210> 12  
<211> 30  
<212> PRT  
<213> Homo sapiens

<400> 12

Glu Tyr Ser His Cys Ala Trp Thr Ile Val Arg Val Glu Ile Leu Arg  
1 5 10 15

Asn Phe Tyr Phe Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn  
20 25 30

<210> 13  
<211> 47  
<212> PRT  
<213> Homo sapiens

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> Xaa is methionine sulfoxide

<400> 13

B<sub>1</sub>  
Glu Asp Ala Ala Leu Thr Ile Tyr Glu Xaa Leu Gln Asn Ile Phe Ala  
1 5 10 15

Ile Phe Arg Gln Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val  
20 25 30

Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn His Leu Lys  
35 40 45

<210> 14  
<211> 47  
<212> PRT  
<213> Homo sapiens

<400> 14

Glu Asp Ala Ala Leu Thr Ile Tyr Glu Met Leu Gln Asn Ile Phe Ala  
1 5 10 15

Ile Phe Arg Gln Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val  
20 25 30

Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn His Leu Lys  
35 40 45

---